Cargando…

Proteomics-Driven Biomarkers in Pancreatic Cancer

Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramalhete, Luís, Vigia, Emanuel, Araújo, Rúben, Marques, Hugo Pinto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443269/
https://www.ncbi.nlm.nih.gov/pubmed/37606420
http://dx.doi.org/10.3390/proteomes11030024
_version_ 1785093788535881728
author Ramalhete, Luís
Vigia, Emanuel
Araújo, Rúben
Marques, Hugo Pinto
author_facet Ramalhete, Luís
Vigia, Emanuel
Araújo, Rúben
Marques, Hugo Pinto
author_sort Ramalhete, Luís
collection PubMed
description Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which proves to be the most beneficial in tracking treatment response rather than in early detection. In recent years, proteomics has emerged as a powerful tool for advancing our understanding of pancreatic cancer biology and identifying potential biomarkers and therapeutic targets. This review aims to offer a comprehensive survey of proteomics’ current status in pancreatic cancer research, specifically accentuating its applications and its potential to drastically enhance screening, diagnosis, and treatment response. With respect to screening and diagnostic precision, proteomics carries the capacity to augment the sensitivity and specificity of extant screening and diagnostic methodologies. Nonetheless, more research is imperative for validating potential biomarkers and establishing standard procedures for sample preparation and data analysis. Furthermore, proteomics presents opportunities for unveiling new biomarkers and therapeutic targets, as well as fostering the development of personalized treatment strategies based on protein expression patterns associated with treatment response. In conclusion, proteomics holds great promise for advancing our understanding of pancreatic cancer biology and improving patient outcomes. It is essential to maintain momentum in investment and innovation in this arena to unearth more groundbreaking discoveries and transmute them into practical diagnostic and therapeutic strategies in the clinical context.
format Online
Article
Text
id pubmed-10443269
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104432692023-08-23 Proteomics-Driven Biomarkers in Pancreatic Cancer Ramalhete, Luís Vigia, Emanuel Araújo, Rúben Marques, Hugo Pinto Proteomes Review Pancreatic cancer is a devastating disease that has a grim prognosis, highlighting the need for improved screening, diagnosis, and treatment strategies. Currently, the sole biomarker for pancreatic ductal adenocarcinoma (PDAC) authorized by the U.S. Food and Drug Administration is CA 19-9, which proves to be the most beneficial in tracking treatment response rather than in early detection. In recent years, proteomics has emerged as a powerful tool for advancing our understanding of pancreatic cancer biology and identifying potential biomarkers and therapeutic targets. This review aims to offer a comprehensive survey of proteomics’ current status in pancreatic cancer research, specifically accentuating its applications and its potential to drastically enhance screening, diagnosis, and treatment response. With respect to screening and diagnostic precision, proteomics carries the capacity to augment the sensitivity and specificity of extant screening and diagnostic methodologies. Nonetheless, more research is imperative for validating potential biomarkers and establishing standard procedures for sample preparation and data analysis. Furthermore, proteomics presents opportunities for unveiling new biomarkers and therapeutic targets, as well as fostering the development of personalized treatment strategies based on protein expression patterns associated with treatment response. In conclusion, proteomics holds great promise for advancing our understanding of pancreatic cancer biology and improving patient outcomes. It is essential to maintain momentum in investment and innovation in this arena to unearth more groundbreaking discoveries and transmute them into practical diagnostic and therapeutic strategies in the clinical context. MDPI 2023-08-07 /pmc/articles/PMC10443269/ /pubmed/37606420 http://dx.doi.org/10.3390/proteomes11030024 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ramalhete, Luís
Vigia, Emanuel
Araújo, Rúben
Marques, Hugo Pinto
Proteomics-Driven Biomarkers in Pancreatic Cancer
title Proteomics-Driven Biomarkers in Pancreatic Cancer
title_full Proteomics-Driven Biomarkers in Pancreatic Cancer
title_fullStr Proteomics-Driven Biomarkers in Pancreatic Cancer
title_full_unstemmed Proteomics-Driven Biomarkers in Pancreatic Cancer
title_short Proteomics-Driven Biomarkers in Pancreatic Cancer
title_sort proteomics-driven biomarkers in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10443269/
https://www.ncbi.nlm.nih.gov/pubmed/37606420
http://dx.doi.org/10.3390/proteomes11030024
work_keys_str_mv AT ramalheteluis proteomicsdrivenbiomarkersinpancreaticcancer
AT vigiaemanuel proteomicsdrivenbiomarkersinpancreaticcancer
AT araujoruben proteomicsdrivenbiomarkersinpancreaticcancer
AT marqueshugopinto proteomicsdrivenbiomarkersinpancreaticcancer